Project Summary
Our overall strategy for Hesperos is to utilize microphysiological systems in combination with functional
readouts to establish platforms capable of sophisticated analysis of chemicals and drug candidates for toxicity
and efficacy during pre-clinical testing, with initial emphasis on predictive toxicity. This is a service based
company and is developing low-cost in vitro systems utilizing a novel “pumpless” microphysiological platform
described in US Patent 8,748,180B2, June 10, 2014. The compartments each representing a tissue or organ
are connected by a serum-free medium which mimics the blood. The pumpless integrated system, using a
rocking motion to pump the serum-free cellular medium, reduces the complexity and cost of the fluidic circuit
design and simplifies set-up and operation of the device. Hickman has developed microelectrode arrays and
cantilever systems that are integrated on chip that allows for noninvasive electronic and mechanical readouts.
We will utilize microfluidic analytical components with this system for rapid and sensitive biomarker (chemical,
protein and small molecule) assessment. However, the number of biomarkers to be monitored for cell health
and function will be greatly reduced in our systems from use of the functional readouts. We have constructed
physiological systems that represent cardiac, muscle and liver function that are being used at Hesperos and in
Hickman’s lab by pharmaceutical and cosmetic companies. We have demonstrated multi-organ toxicity in the
4-organ system composed of neuronal, cardiac, liver and muscle components. This system is the first
microfluidic model to demonstrate the capacity to promote the survival and functional competence of 4
interconnected tissue modules in serum-free medium over extended culture periods. Further evidence of the
commercial viability of our platform is that we have just been awarded a Phase II SBIR grant from National
Center for Advancing Translational Sciences (NCATS) to apply advanced manufacturing techniques to our
basic 4-organ platform in collaboration with National Institute of Standards and Technology (NIST).
In this proposal we extend the 4 organ system to include a model of the human kidney as a step toward a
more complete ADMETox model. Our first aim will be to design, fabricate and test a kidney module to model
aspects of elimination through the kidney. We will then incorporate the kidney module with the existing 4 organ
module. This requires the addition of another layer to allow flow of a dialysis stream to mimic excretion through
the kidney. The kidney will have glomerulus and proximal tubule compartments. Electrodes to directly measure
TEER (transepithelial electrical resistance) will be integrated into the kidney module. The existing system will
measure functional readouts of force for skeletal muscle and cardiac, and electrical activity of neurons and
patterned cardiomyocytes. The system will be validated with drugs and chemicals that have shown to effect
kidney function.